List of claims

Claims 1-45 (canceled)

46. (new) The (R) isomer of a compound according to formula **I** wherein:



Formula **I**

R^1 is (C_{1-6})alkyl;

R^2 is halogen or -OR';

R^3 is hydrogen or -OR';

R' is hydrogen, (C_{1-6})alkyl, or SO_2R";

R" is (C_{1-6})alkyl, haloalkyl,

aryl or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with a group selected from (C_{1-6})alkyl, halo, haloalkyl, cyano, nitro, alkylsulfonyl, and alkylsulfonylamino;

R^4 is (i) (C_{1-6})alkyl, (ii) aryl, heterocyclyl, or heteroaryl, wherein said aryl, heterocyclyl or heteroaryl groups are optionally substituted with a group selected from (C_{1-6})alkyl, halo, haloalkyl, (C_{1-6})alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urea, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxycarbonyl, heterocyclyl and heteroaryl, or (iii) $-NR^5R^6$; and

R^5 and R^6 are independently of each other hydrogen, (C_{1-6})alkyl, aryl or heterocyclyl; wherein said aryl or heterocyclyl groups are optionally substituted with (C_{1-6})alkyl, halo, haloalkyl, cyano, (C_{1-6})alkoxy, and alkylsulfonyl;

or an individual isomer, a racemic or non-racemic mixture of isomers, or an acceptable salt or solvate thereof; with the proviso that the compound is other than {4-[((R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone.

47. (new) The compound of Claim 46, wherein R^2 is (C_{1-6})alkoxy and R^3 is hydrogen.

48. (new) The compound of Claim 46, wherein R^2 is (C_{1-6})alkoxy and R^3 is (C_{1-6})alkoxy.

49. (new) The compound of Claim 46, wherein R^2 is $-OSO_2R''$ and R^3 is hydrogen.

50. (new) The compound of Claim 46, wherein R^2 is hydroxy and R^3 is hydrogen.

51. (new) The compound of Claim 46, wherein R^2 is halogen and R^3 is hydrogen.

52. (new) The compound of Claim 46 wherein R^4 is (C_{1-6})alkyl.

53. (new) The compound of Claim 52, wherein R^1 is ethyl or propyl.

54. (new) The compound of Claim 53, wherein R^2 is -OR', and R^3 is -OR' or hydrogen.

55. (new) The compound of Claim 46, wherein R^4 is an aryl group.

56. (new) The compound of Claim 55, wherein R^4 is phenyl optionally substituted with a group selected from (C_{1-6})alkyl, halo, haloalkyl, (C_{1-6})alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urea, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxycarbonyl, heterocyclyl and heteroaryl.

57. (new) The compound of Claim 55, wherein R^1 is ethyl or propyl.

58. (new) The compound of Claim 56, wherein R^1 is ethyl or propyl.

59. (new) The compound of Claim 58, wherein R^2 is -OR', and R^3 is -OR' or hydrogen.

60. (new) The compound of Claim 46, wherein R^4 is a heteroaryl group.

61. (new) The compound of Claim 60, wherein R^4 is selected from furanyl, thiophenyl, isooxazolyl, oxazolyl, imidazolyl, and pyrazolyl, all optionally substituted with one or two (C_{1-6}) alkyl.

62. (new) The compound of Claim 60, wherein R^1 is ethyl or propyl.

63. (new) The compound of Claim 61, wherein R^1 is ethyl or propyl.

64. (new) The compound of Claim 63, wherein R^2 is -OR', and R^3 is -OR' or hydrogen.

65. (new) The compound of Claim 46, wherein R^4 is a heterocyclyl group.

66. (new) The compound of Claim 65, wherein R^4 is piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, or diazepanyl, all optionally substituted with one or two (C_{1-6})alkyl or alkylcarbonyl groups.

67. (new) The compound of Claim 65, wherein R^4 is piperidin-4-yl, optionally substituted with one or two (C_{1-6})alkyl groups or alkylcarbonyl groups.

68. (new) The compound of Claim 65, wherein R^4 is piperidin-1-yl, optionally substituted with one or two (C_{1-6})alkyl groups.

69. (new) The compound of Claim 65, wherein R^4 is pyrrolidin-1-yl, optionally substituted with one or two (C_{1-6})alkyl groups.

70. (new) The compound of Claim 65 wherein R^4 is [1,4]-diazepany-1-yl, optionally substituted with one or two (C_{1-6})alkyl groups.

71. (new) The compound of Claim 65, wherein R^4 is piperazin-1-yl, optionally substituted with one or two (C_{1-6})alkyl groups.

72. (new) The compound of Claim 65, wherein R^4 is morpholinyl, optionally substituted with one or two (C_{1-6})alkyl groups.

73. (new)The compound of Claim 65, wherein R^1 is ethyl or propyl.

74. (new) The compound of Claim 66, wherein R^1 is ethyl or propyl.

75. (new) The compound of Claim 74, wherein R^2 is -OR', and R^3 is -OR' or hydrogen.

76. (new) The compound of Claim 46, wherein R^4 is $-NR^5R^6$.

77. (new) The compound of Claim 76, wherein R^5 is (C_{1-6})alkyl, and R^6 is hydrogen or (C_{1-6})alkyl.

78. (new) The compound of Claim 76, wherein R^1 is ethyl or propyl.

79. (new) The compound of Claim 78, wherein R^2 is -OR', and R^3 is -OR' or hydrogen.

80. (new) The compound of Claim 46, comprising:

{4-[((R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperazin-1-yl-methanone;

{4-[((R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-morpholin-4-yl-methanone;

{4-[((R)-6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone;

1-{4-[((R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-ethanone;

{4-[((R)-6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperazin-1-yl-methanone;

{4-[((R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-(4-methyl-piperazin-1-yl)-methanone; and

{4-[((R)-7-Bromo-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone.

81. (new)A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 46 in admixture with an acceptable carrier.

82. (new) The pharmaceutical composition of Claim 81, wherein the compound is suitable for administration to a subject having a disease state which is alleviated by treatment with a M2/M3 muscarinic receptor antagonist.

83. (new) A method of treating a subject which comprises administering to the subject with a disease treatable with a M2/M3 muscarinic antagonist a therapeutically effective amount of one or more compounds of Claim 46.

84. (new) The method of Claim 83, wherein the disease state is associated with smooth muscle disorders comprising diseases of the genitourinary or gastrointestinal tract, or of respiratory states.

85. (new) The method of Claim 84, wherein the disease state is associated with the genitourinary tract.

86. (new) The method of Claim 85, wherein the disease state comprises overactive bladder, detrusor hyperactivity, urgency, frequency, reduced bladder capacity, incontinence episodes, changes in bladder capacity, micturition threshold, unstable bladder contractions, sphincteric spasticity, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, idiopathy conditions, or detursor instability.

87. (new) The method of treatment of Claim 84, wherein the disease state comprises respiratory states.

88. (new) The method of treatment of Claim 87, wherein the disease state comprises respiratory states from allergies or asthma.

89. (new) The method of treatment of Claim 84, wherein the disease state comprises gastrointestinal tract disorders.

90. (new) A process for preparing a compound as claimed in Claim 46 which process comprises reacting a compound having a general formula **d**:



d

wherein R^1, R^2 and R^3 are as described in Claim 46,

with a compound of general Formula $R^4C(O)L$, wherein L is a leaving group and R^4 is as described in Claim 46,

to prepare a compound of Formula **I**



I

wherein R^1, R^2, R^3 and R^4 are as described in Claim 46.